Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Baxter
McKinsey
Mallinckrodt
Colorcon

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Vaniprevir

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Vaniprevir?

Vaniprevir is an investigational drug.

There have been 11 clinical trials for Vaniprevir. The most recent clinical trial was a Phase 3 trial, which was initiated on August 1st 2011.

The most common disease conditions in clinical trials are Hepatitis C, Hepatitis, and Hepatitis A. The leading clinical trial sponsors are Merck Sharp & Dohme Corp. and [disabled in preview].

There are fifteen US patents protecting this investigational drug and two hundred and nine international patents.

Recent Clinical Trials for Vaniprevir
TitleSponsorPhase
Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048)Merck Sharp & Dohme Corp.Phase 1
Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045)Merck Sharp & Dohme Corp.Phase 3
Study of Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed After Treatment (MK-7009-044)Merck Sharp & Dohme Corp.Phase 3

See all Vaniprevir clinical trials

Clinical Trial Summary for Vaniprevir

Top disease conditions for Vaniprevir
Top clinical trial sponsors for Vaniprevir

See all Vaniprevir clinical trials

US Patents for Vaniprevir

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Vaniprevir   Start Trial HCV NS3 protease inhibitors Merck & Co., Inc. (Rahway, NJ)   Start Trial
Vaniprevir   Start Trial HCV NS3 protease inhibitors Merck Sharp & Dohme Corp. (Rahway, NJ)   Start Trial
Vaniprevir   Start Trial Methods for treating HCV AbbVie Inc. (North Chicago, IL)   Start Trial
Vaniprevir   Start Trial Processes for preparing protease inhibitors of hepatitis C virus Merck Sharp & Dohme Corp. (Rahway, NJ)   Start Trial
Vaniprevir   Start Trial Methods for treating HCV AbbVic Inc. (North Chicago, IL)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Vaniprevir

Drugname Country Document Number Estimated Expiration Related US Patent
Vaniprevir Argentina 057456 2025-07-20   Start Trial
Vaniprevir Austria 443075 2025-07-20   Start Trial
Vaniprevir Australia 2006276189 2025-07-20   Start Trial
Vaniprevir Brazil PI0613633 2025-07-20   Start Trial
Vaniprevir Canada 2615022 2025-07-20   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Baxter
Moodys
AstraZeneca
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.